A one-day BioM and Lonza virtual symposium, to gain insight and discuss
BioM and Lonza are pleased to invite you to join them for a complimentary symposium, digitally delivered on 18 June 2020, to gain insight from experts, in the different approaches and techniques to successfully progress therapeutic proteins from discovery to the clinic.
Enjoy an industry perspective from a seasoned pharmaceutical executive, together with updates to approaches with new and established technologies enabling translational research, from Lonza specialists, local companies and leading academics.
Pre-book 1-on-1 sessions with our scientific experts at the Virtual Drop-in-Clinics that will follow the presentations.
Registration
Attendance at this event is complimentary and by invitation.
For more information, including the latest agenda and to register, please visit: http://www.bio-m.org/
Insight and discussion with our experts
Agenda
09.00 – 09.10 | Welcome: Prof. Dr. Horst Domdey, CEO, BioM Dr. Sarah Holland | Global Head of Licensing, Lonza |
09.10 – 09.45 | Keynote: An Industry perspective – What to consider when moving therapeutic proteins from development to first in human trials Dr. Hari Kumar | Pharmaceutical Executive; Independent Board Member; former CEO Adheron Therapeutics |
09.45 – 10:20 | Developability assessment tools and de-risking strategies to support progression of biologics from discovery to development Dr. Noel Smith | Principal, Applied Protein Services, Lonza |
10:20 – 10.45 | PASylation®: an enabling technology to create biobetters with extended half-life and enhanced action Prof. Dr. Arne Skerra | Chairman & Founder, XL-protein GmbH |
10.45 – 11.00 | Virtual coffee break |
11.00 – 11.35 | Approaches to maximise successful development of cell lines expressing more complex proteins – including bispecific antibodies Dr. Alison Porter | Head of Expression System Sciences, Lonza |
11.35 – 12.00 | Antibodies against complex molecules Dr. Annika Schmid | Associate Director, MorphoSys AG |
12.00 – 12.35 | A step forward – Combined strategies to enhance the performance of Pichia pastoris Joachim Klein | Head of Strain Development and Cell Banking, Microbial Development Services, Lonza |
12.35 – 13.00 | Accelerating a diverse pipeline of antibody-based medicines to the clinic Dr. Carsten Brockmeyer | CEO, Formycon AG |
13.00 – 13.30 | Virtual lunch break |
13.30 – 13.55 | Dual-specific antibodies – Fusing tumor targeting and CD47 immune checkpoint blockade Dr. Nadja Fenn | Project leader of the Exist-funded project OPSYON, Gene Center of the Ludwig-Maximilians University Munich Virtual Drop-in-Clinics start |
13.55 – 14.20 | Anticalin® platform technology for innovative, cutting-edge protein therapeutics against respiratory diseases and cancer Dr. Goran Martić | Senior Alliance Manager, Pieris Pharmaceuticals GmbH Virtual Drop-in-Clinics continue |
14.20 – 15.00 | Q&A session with all speakers | Virtual Drop-in-Clinics continue |
15.00 | Virtual symposium ends | Virtual Drop-in-Clinics continue |